Impact of Respiratory Syncytial Virus-Confirmed Hospitalizations on Caregivers of US Preterm Infants
- PMID: 31007050
- PMCID: PMC6552118
- DOI: 10.1177/0009922819843639
Impact of Respiratory Syncytial Virus-Confirmed Hospitalizations on Caregivers of US Preterm Infants
Abstract
This study assessed the impact of respiratory syncytial virus-confirmed hospitalizations (RSVH) on caregivers of high-risk preterm infants. Caregivers for infants born at 29 to 35 weeks' gestational age and hospitalized for confirmed RSV disease responded to measures of self-rated and perceived infant stress (1-7; 7 = very stressful), perceived infant health (0-100; 100 = best imaginable health), and productivity impairment. Data were collected at hospital discharge through 1 month post-discharge. Caregiver responses indicated high stress levels, poor health, and productivity loss were reported at discharge; however, steady improvements were seen through 1 month post-discharge: caregiver-rated stress (from 6 to 2), infant stress (5 to 1), caregiver-perceived infant health (64 to 84), and productivity loss (mothers: 91% to 31%; fathers: 81% to 18%). Qualitative results indicated emotional impact, family routine disruption, financial concerns, and medical concerns persisted at 1 month post-discharge. This study found the caregiver burden of RSVH persists at least 1 month beyond discharge.
Keywords: caregiver burden; hospitalization; infant; preterm; respiratory syncytial virus.
Conflict of interest statement
Figures





Similar articles
-
The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery.Pediatrics. 2005 Jun;115(6):1536-46. doi: 10.1542/peds.2004-1149. Pediatrics. 2005. PMID: 15930214
-
SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.Am J Perinatol. 2020 Mar;37(4):421-429. doi: 10.1055/s-0039-1681014. Epub 2019 Apr 16. Am J Perinatol. 2020. PMID: 30991438
-
Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.Pediatr Infect Dis J. 2017 Feb;36(2):160-167. doi: 10.1097/INF.0000000000001377. Pediatr Infect Dis J. 2017. PMID: 27755464 Free PMC article.
-
Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies.PLoS One. 2020 Feb 21;15(2):e0229357. doi: 10.1371/journal.pone.0229357. eCollection 2020. PLoS One. 2020. PMID: 32084214 Free PMC article.
-
A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.J Infect Dis. 2022 Aug 15;226(Suppl 2):S195-S212. doi: 10.1093/infdis/jiac201. J Infect Dis. 2022. PMID: 35968876 Free PMC article.
Cited by
-
The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis.J Infect Dis. 2022 Aug 15;226(Suppl 2):S143-S147. doi: 10.1093/infdis/jiac211. J Infect Dis. 2022. PMID: 35968867 Free PMC article. No abstract available.
-
Burden of respiratory syncytial virus disease in infants and the potential value of maternal immunization in Greece.Front Public Health. 2025 Jul 16;13:1611483. doi: 10.3389/fpubh.2025.1611483. eCollection 2025. Front Public Health. 2025. PMID: 40740353 Free PMC article.
-
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.BMC Infect Dis. 2024 Jan 18;24(1):99. doi: 10.1186/s12879-024-08988-9. BMC Infect Dis. 2024. PMID: 38238680 Free PMC article.
-
Impact of Child Respiratory Syncytial Virus-Confirmed Infections on Caregivers in Japan: A Web-Based Survey.J Clin Med. 2024 Sep 10;13(18):5355. doi: 10.3390/jcm13185355. J Clin Med. 2024. PMID: 39336842 Free PMC article.
-
The Estimate of Parental Quality of Life Loss Due to Respiratory Syncytial Virus (RSV) Hospitalization.Diseases. 2023 Sep 24;11(4):126. doi: 10.3390/diseases11040126. Diseases. 2023. PMID: 37873770 Free PMC article.
References
-
- Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(suppl 51):S127-S132. - PubMed
-
- Boyce TG, Mellen BG, Mitchel EF, Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-870. - PubMed
-
- Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341-e348. - PubMed
-
- The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 pt 1):531-537. - PubMed
-
- Blanken MO, Rovers MM, Molenaar JM, et al. ; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-1799. - PubMed